Marcella McGuffin, PA
Medical · Ashland, KYNPI 1891747432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 475 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$386
- AstraZeneca$337
- Kowa Pharmaceuticals America, Inc.$315
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,194100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 104 | $1,424 |
| Novo Nordisk | 90 | $1,291 |
| Lilly USA, LLC | 66 | $1,016 |
| Sanofi-aventis U.S. LLC | 25 | $386 |
| AstraZeneca(2 entities) | 22 | $337 |
| Kowa Pharmaceuticals America, Inc. | 25 | $315 |
| Boehringer Ingelheim | 21 | $302 |
| Dexcom, Inc. | 11 | $293 |
| AbbVie | 16 | $281 |
| Amarin Pharma, Inc. | 20 | $245 |
| Amgen(2 entities) | 13 | $205 |
| Corcept Therapeutics | 6 | $124 |
| Insulet Corporation | 6 | $115 |
| Ascendis Pharma Endocrinology Inc | 7 | $104 |
| Medtronic | 3 | $93 |
| Tandem Diabetes Care, Inc. | 5 | $92 |
| Xeris Pharmaceuticals, Inc. | 4 | $68 |
| Novartis | 3 | $60 |
| BETA Bionics, Inc. | 3 | $53 |
| Bayer | 3 | $53 |
| IBSA Pharma Inc. | 3 | $53 |
| Merck | 3 | $41 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Sequel Med Tech, LLC | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 2 | $23 |
| Medicure Pharma Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $12 |
How this compares
$7,205 in reported general payments places this provider in the 90th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 312 | $480,092 |
| MounjaroTirzepatide | 145 | $212,255 |
| JardianceEmpagliflozin | 177 | $193,832 |
| TrulicityDulaglutide | 117 | $175,969 |
| FarxigaDapagliflozin Propanediol | 122 | $135,378 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $133,817 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $120,376 |
| JanuviaSitagliptin Phosphate | 44 | $60,883 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $59,550 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $42,747 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $40,325 |
| VascepaIcosapent Ethyl | 58 | $39,533 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $38,143 |
| Humalog Kwikpen U-100Insulin Lispro | 74 | $36,282 |
| Novolog FlexpenInsulin Aspart | 75 | $34,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $1,291 | $513,869364 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,016 | $399,746327 claims |
| Boehringer IngelheimJardiance, Tradjenta | $302 | $203,329189 claims |
| AstraZenecaFarxiga | $337 | $135,378122 claims |
| MerckJanuvia, Janumet Xr | $41 | $71,06055 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $386 | $20,40512 claims |
| AbbVieSynthroid | $281 | $18,520314 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $8,961876 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 medical providers in Kentucky.
Other medical in Ashland
- Brittany StewartAshland$6K
- Brandi ManningAshland$5K
- Jeanetta Savage BrownAshland$4K
- Deann BrownAshland$3K
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
- Alexandra HuettLouisville$13K
- Danny ThackerFrankfort$11K
- Jessica FrizzellPaducah$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.